These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17220283)

  • 1. It is too early to know if intelligence determines cancer incidence and survival.
    Aapro MS
    Ann Oncol; 2007 Jan; 18(1):4-5. PubMed ID: 17220283
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits and risks of colorectal cancer screening.
    Riemann JF; Schröder C; Kallenbach M; Giersiepen K; Schmoll HJ
    Oncol Res Treat; 2014; 37 Suppl 3():11-20. PubMed ID: 25195828
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer statistics: everything you wanted to know about the cancer registry data but were too afraid to ask.
    Giles GG; Thursfield V
    ANZ J Surg; 2004 Nov; 74(11):931-4. PubMed ID: 15550077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What rate of cure for cancer?].
    Hill C
    Bull Cancer; 1998 Sep; 85(9):745-6. PubMed ID: 9817057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intensive care in oncology].
    Kochanek M; Wendtner C; Shimabukuro-Vornhagen A; Böll B; von Bergwelt-Baildon M
    Dtsch Med Wochenschr; 2014 Apr; 139(14):690-2. PubMed ID: 24623358
    [No Abstract]   [Full Text] [Related]  

  • 6. Deceiving numbers: survival rates and their impact on doctors' risk communication.
    Wegwarth O; Gaissmaier W; Gigerenzer G
    Med Decis Making; 2011; 31(3):386-94. PubMed ID: 21191123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suicide after childhood cancer.
    Howard RA; Inskip PD; Travis LB
    J Clin Oncol; 2007 Feb; 25(6):731; author reply 733-4. PubMed ID: 17308281
    [No Abstract]   [Full Text] [Related]  

  • 8. Excess mortality as an epidemic intelligence tool in chikungunya mapping.
    Ramchurn SK; Goorah SS; Makhan M; Moheeput K
    Euro Surveill; 2008 Feb; 13(7):. PubMed ID: 18445418
    [No Abstract]   [Full Text] [Related]  

  • 9. Sunlight and reduced risk of cancer: is the real story vitamin D?
    Egan KM; Sosman JA; Blot WJ
    J Natl Cancer Inst; 2005 Feb; 97(3):161-3. PubMed ID: 15687354
    [No Abstract]   [Full Text] [Related]  

  • 10. [Which cancerous diseases are significant for the risk assessment when underwriting life insurance?].
    Akermann S
    Versicherungsmedizin; 2005 Sep; 57(3):127-32. PubMed ID: 16180532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Family history and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC).
    Kikuchi S;
    Asian Pac J Cancer Prev; 2007; 8 Suppl():21-4. PubMed ID: 18260703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caution needed for country-specific cancer survival.
    Autier P; Boniol M
    Lancet; 2011 Jan; 377(9760):99-101. PubMed ID: 21215872
    [No Abstract]   [Full Text] [Related]  

  • 13. Historical cancer incidence and mortality assessment in an Illinois community proximal to a former manufactured gas plant.
    Alexander DD; Jiang X; Bylsma LC; Garabrant DH; Irvin SR; Fryzek JP
    BMJ Open; 2014 Dec; 4(12):e006713. PubMed ID: 25534215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experts debate message sent by increased cancer survival rates.
    Twombly R
    J Natl Cancer Inst; 2004 Oct; 96(19):1412-3. PubMed ID: 15467025
    [No Abstract]   [Full Text] [Related]  

  • 15. Accounting for death as a competing risk in cancer-associated thrombosis studies.
    Campigotto F; Neuberg D; Zwicker JI
    Thromb Res; 2012 Apr; 129 Suppl 1():S85-7. PubMed ID: 22682141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When do changes in cancer survival mean progress? The insight from population incidence and mortality.
    Cho H; Mariotto AB; Schwartz LM; Luo J; Woloshin S
    J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):187-97. PubMed ID: 25417232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing changes in the impact of cancer on population survival without considering cause of death.
    Brown BW; Brauner C; Levy LB
    J Natl Cancer Inst; 1997 Jan; 89(1):58-65. PubMed ID: 8978407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The apparent increase in cancer survival].
    Lenner P; Wiklund F
    Lakartidningen; 1995 May; 92(22):2321-4. PubMed ID: 7783495
    [No Abstract]   [Full Text] [Related]  

  • 20. Antineoplastic chemotherapy in cancer patients with methicillin-resistant Staphylococcus aureus (MRSA).
    Crysandt M; Lemmen SW; Jost E; Brummendorf TH; Osieka R; Wilop S
    Onkologie; 2010; 33(11):598-603. PubMed ID: 20975306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.